10.1136/jitc-2020-001806 - KEYNOTE-022 part 3: a randomized, dou...

This document has been corrected

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

10.1136/jitc-2020-001806

Published Online: 2020-12-?

Journal: Journal for ImmunoTherapy of Cancer•Publisher: BMJ

Authors: Anna Maria Di Giacomo•Antoni Ribas•Eduard Gasal•Elizabeth S Croydon•Georgina V Long•Henrik Schmidt•Inge Marie Svane•Jacob Schachter•Mahmoud Abu-Amna•Michal Lotem•Michele Del Vecchio•Paola Queirolo•Paolo Antonio Ascierto•Pier Francesco Ferrucci•Razi Ghori•Rosalie Stephens•Scott J Diede•Victoria Atkinson

This document has been corrected

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

10.1136/jitc-2020-001806

Published Online: 2020-12-?

Journal: Journal for ImmunoTherapy of Cancer

NOW

2021-11-15•Correction

Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

10.1136/jitc-2020-001806corr1

* information provided by CrossRef

2021-11-15•Correction

10.1136/jitc-2020-001806corr1

* information provided by CrossRef

2020-12-?•Published

2021-11-15•Correction

Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

10.1136/jitc-2020-001806corr1

* information provided by CrossRef

This document has been corrected

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

10.1136/jitc-2020-001806

Published Online: 2020-12-?

Journal: Journal for ImmunoTherapy of Cancer•Publisher: BMJ